Opinion

Published within

« | ... | 1560 | 1561 | 1562 | 1563 | 1564 | 1565 | 1566 | 1567 | 1568 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

Biogenerics: the battle is only just beginning

Biogenerics - also known as biosimilars or follow-on protein products - are set to become the next big battleground between branded pharma and the generics industry. Biological therapeutics such as epoetin are currently huge money-spinners for big pharma and unsurprisingly, generics players want a slice of the action.

Published By Datamonitor
18 Jan 2006
CommentWire
CommentWire

Biogenerics: pros will outweigh cons

The sizable therapeutic proteins market is becoming increasingly attractive to generics manufacturers. The high prices of therapeutic protein products also mean that any cost savings to the payer, regardless of how small, could be a significant driving force. Many generics producers are consequently making strategic moves in this direction and an approval pathway should be in place within years.

Published By Datamonitor
03 Mar 2003
Expert View
Expert View

Biogenerics market presents new commercial opportunity

With several blockbuster biological products approaching patent expiry and the emergence of new approval pathways, the biogenerics segment represents an attractive opportunity for companies looking to escape intensifying competition in the commodity generics sector. However, with the biotech industry opposed to any new regulatory initiatives, barriers to market entry could remain high.

Published By Datamonitor
11 Jun 2004
CommentWire
CommentWire

Biogen: new indication for Avonex

Official EU approval is almost certain within a few months, making Avonex the first disease-modifying MS drug to be indicated for early treatment. Biogen is wise to move the drug into new geographies and new indications: its orphan drug status in the US (its largest market) is set to end next year at the latest.

Published By Datamonitor
07 Mar 2002
CommentWire
CommentWire

Biogen: losing out to Serono

Biogen's announcement is a major blow, since the multiple sclerosis drug is critical to the company's short to mid-term growth prospects. Although Biogen blames a weakening overall market for multiple sclerosis drugs, it looks like - as Datamonitor predicted - the truth has more to do with the new entry and high uptake of Serono's Rebif.

Published By Datamonitor
12 Jun 2002
CommentWire
CommentWire

Biogen: Amevive decision eases Avonex woes

Biogen's Amevive has moved a step closer to the market, as an FDA panel urged its approval for treating adult chronic psoriasis. If the drug is approved, it will be a welcome diversification for Biogen. Its only marketed product, MS drug Avonex, is under serious threat from the FDA's recent decision to approve Serono's Rebif in the US.

Published By Datamonitor
29 May 2002
CommentWire
CommentWire

Biogen/Serono: the US launch of Rebif draws nearer

If next month's FDA meeting gives the go-ahead, Serono will launch its rival multiple sclerosis treatment Rebif in the US straight away. Due to its superior trial results, Rebif could then bring the end of Avonex's global market dominance. This would be a serious setback for Biogen, which is heavily dependent on the drug's revenues.

Published By Datamonitor
14 Feb 2002
CommentWire
CommentWire

Biogen/Serono: pistols at dawn

Published By Datamonitor
29 Jun 2001
CommentWire
CommentWire

Biogen/Idec: still a matter of size

Idec Pharmaceuticals [IDPH] and Biogen [BGEN], both mid-life biotechnology companies, have signed a definitive merger agreement. Combining resources could help speed cancer and autoimmune products toward commercialization. However, the merger is likely to have a more pronounced near-term effect on the companies' licensing strategies.<BR />

Published By Datamonitor
25 Jun 2003
CommentWire
CommentWire

Biogen-IDEC / Elan: Tysabri affirms its potential

Biogen-IDEC [BIIB] and Elan [ELA.L] have announced that Tysabri has demonstrated significant improvements in disability progression and reduction in the rate of relapse in relapse-remitting multiple sclerosis (RRMS). The outlook for the drug is therefore extremely bright, and it could cannibalize revenues of rival RRMS products significantly. Tysabri may yet herald a new dawn in RRMS treatment.

Published By Datamonitor
18 Feb 2005

« | ... | 1560 | 1561 | 1562 | 1563 | 1564 | 1565 | 1566 | 1567 | 1568 | ... | » »|

No help is available.